Publications by authors named "Christopher Lord"

Claim this Profile
R
Recognising serous atrophy of bone marrow: a review of imaging findings.
Tania Toma, Stuart Viegas, Dimitri Amiras, Christopher Lord

Skeletal Radiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens.
Hans Wildiers, Virginie Adam, Seamus O'Reilly, Josephine Van Cauwenberge, Amal Arahmani, Christopher J Lord

JAMA Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the detection of paediatric ankle fractures with zero echo time imaging: A case of an occult salter-harris III ankle fracture.
Tania Toma, Kifle Tekle, Joely Smith, Rebecca Quest, Rachel Kelly, Christopher Lord

Emerg Radiol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NASP modulates histone turnover to drive PARP inhibitor resistance.
Sarah C Moser, Anna Khalizieva, Josef Roehsner, Elisabeth Pottendorfer, Milo L Kaptein, Christopher J Lord

Nature· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma.
Katharine J Herbert, Rosie Upstill-Goddard, Stephan B Dreyer, Selma Rebus, Christian Pilarsky, Christopher J Lord

Br J Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial.
Magnus T Dillon, Emmanuel C Patin, Kabir Mohammed, Jeane Guevara, Simon A Smith, Christopher J Lord

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models.
Joan Kyula-Currie, Victoria Roulstone, James Wright, Francesca Butera, Arnaud Legrand, Christopher J Lord

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.
Victoria Roulstone, Joan Kyula-Currie, James Wright, Emmanuel C Patin, Isaac Dean, Christopher J Lord

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers.
Roman M Chabanon, Liudmila Shcherbakova, Magali Lacroix-Triki, Marine Aglave, Jean Zeghondy, Christopher J Lord

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib and dsRNA sensor co-operate to enhance anti-cancer effects through ER stress and modulation of immune evasion.
Victoria Roulstone, Joan Kyula-Currie, James Wright, Emmanuel C Patin, Isaac Dean, Christopher J Lord

Nat Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma.
James Stewart, Dragomir B Krastev, Rachel Brough, Diana Zatreanu, Feifei Song, Christopher J Lord

Oncogene· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The transcriptomic architecture of common cancers reflects synthetic lethal interactions.
Syed Haider, Rachel Brough, Santiago Madera, Jacopo Iacovacci, Aditi Gulati, Christopher J Lord

Nat Genet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proteogenomic discovery of -defective phenocopy in cancer predicts disease outcome, response to treatment, and therapeutic targets.
Jacopo Iacovacci, Rachel Brough, Fatemeh Ahmadi Moughari, John Alexander, Harriet Kemp, Christopher J Lord

Sci Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Replication Stress Is an Actionable Genetic Vulnerability in Desmoplastic Small Round Cell Tumors.
Asuka Kawai-Kawachi, Madison M Lenormand, Clémence Astier, Noé Herbel, Meritxell B Cutrona, Christopher J Lord

Cancer Res· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.
Fresia Pareja, Rohit Bhargava, Virginia F Borges, Edi Brogi, Rita Canas Marques, Christopher J Lord

NPJ Breast Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer.
George Seed, Nick Beije, Wei Yuan, Claudia Bertan, Jane Goodall, Christopher J Lord

Cancer Cell· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13.
Jean Ching-Yi Tien, Jie Luo, Yu Chang, Yuping Zhang, Yunhui Cheng, Christopher J Lord

Cell Rep Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.
Anthony Cheung, Alicia M Chenoweth, Annelie Johansson, Roman Laddach, Naomi Guppy, Christopher J Lord

Clin Cancer Res· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNASEH2B loss and PARP inhibition in advanced prostate cancer.
Juliet Carmichael, Ines Figueiredo, Bora Gurel, Nick Beije, Wei Yuan, Christopher J Lord

J Clin Invest· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathway-based signatures predict patient outcome, chemotherapy benefit and synthetic lethal dependencies in invasive lobular breast cancer.
John Alexander, Koen Schipper, Sarah Nash, Rachel Brough, Harriet Kemp, Christopher J Lord

Br J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality.
Jean Ching-Yi Tien, Yu Chang, Yuping Zhang, Jonathan Chou, Yunhui Cheng, Christopher J Lord

bioRxiv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Joseph S Baxter, Rachel Brough, Dragomir B Krastev, Feifei Song, Sandhya Sridhar, Christopher J Lord

Mol Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complex synthetic lethality in cancer.
Colm J Ryan, Lovely Paul Solomon Devakumar, Stephen J Pettitt, Christopher J Lord

Nat Genet· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting Cancer Synthetic Lethality in Cancer-Lessons Learnt from PARP Inhibitors.
Stephen J Pettitt, Colm J Ryan, Christopher J Lord

Cancer Treat Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
Philip Bland, Harry Saville, Patty T Wai, Lucinda Curnow, Gareth Muirhead, Christopher J Lord

Nat Genet· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis